Szela Mary T — SEC insider filings
SEC reporting owner CIK 1410289. 32 insider filings on record with FilingPulse; latest filed 2026-11-19.
Transaction summary — filings shown
Covers all 32 filings on record, filed 2021-01-13 to 2026-11-19. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 13 legs across 8 filings — 187,658 shares, $739,110 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 2 legs across 1 filing — 20,302 shares, $79,383 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 33.
- Largest priced transaction: purchase of 12,900 shares @ $11.54 ($148,866) in Absci Corp, filed 2026-07-06.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| TriSalus Life Sciences, Inc. (TLSI) | CEO and President, Director | 14 | 12 legs · 174,758 sh · $590,244 | 2 legs · 20,302 sh · $79,383 | 12 |
| Absci Corp (ABSI) | Director | 4 | 1 leg · 12,900 sh · $148,866 | — | 5 |
| Kura Oncology, Inc. (KURA) | Director | 6 | — | — | 6 |
| Prometheus Biosciences, Inc. (RXDX) | Director | 4 | — | — | 6 |
| Omega Therapeutics, Inc. (OMGA) | Director | 3 | — | — | 3 |
| Coherus BioSciences, Inc. (CHRS) | Director | 1 | — | — | 1 |
Insider filings — Szela Mary T
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-19 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Purchase (P): 30,864 @ $2.31 · Purchase (P): 34,328 @ $2.59 | EDGAR |
| 2026-10-07 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Tax withholding (F): 2,693 @ $4.38 | EDGAR |
| 2026-07-06 | 4 | Absci Corp (ABSI) | Purchase (P): 12,900 @ $11.54 | EDGAR |
| 2026-07-01 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Grant/award (A): 3,990 @ $3.87 | EDGAR |
| 2026-06-15 | 4/A | Absci Corp (ABSI) | Grant/award (A): 8,400 @ $0 · Grant/award (A): 33,200 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Absci Corp (ABSI) | Grant/award (A): 10,100 @ $0 · Grant/award (A): 39,800 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Purchase (P): 39,682 @ $2.59 | EDGAR |
| 2026-03-20 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Sale (S): 4,358 @ $4.13 · Sale (S): 15,944 @ $3.85 | EDGAR |
| 2026-02-23 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Purchase (P): 30,487 @ $4.10 | EDGAR |
| 2025-11-25 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Grant/award (A): 125,000 @ $0 · Grant/award (A): 125,000 @ $0 · Grant/award (A): 300,000 @ $0 · Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-07-09 | 4 | Absci Corp (ABSI) | Grant/award (A): 178,400 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 28,500 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Grant/award (A): 21,089 @ $0 | EDGAR |
| 2025-01-31 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Purchase (P): 5,030 @ $5.03 · Purchase (P): 5,010 @ $5.28 | EDGAR |
| 2025-01-29 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Grant/award (A): 40,000 @ $0 · Purchase (P): 4,826 @ $5.42 · Purchase (P): 4,716 @ $5.12 · Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2024-09-13 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Purchase (P): 7,520 @ $5.20 · Purchase (P): 1,295 @ $4.83 · Purchase (P): 6,000 @ $5 | EDGAR |
| 2024-09-12 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Purchase (P): 5,000 @ $4.97 | EDGAR |
| 2024-06-21 | 4 | Omega Therapeutics, Inc. (OMGA) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Grant/award (A): 84,899 @ $0 · Grant/award (A): 288,750 (derivative) @ $0 | EDGAR |
| 2023-08-15 | 4 | TriSalus Life Sciences, Inc. (TLSI) | Grant/award (A): 172,500 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | Prometheus Biosciences, Inc. (RXDX) | Disposition to issuer (D): 2,071 · Disposition to issuer (D): 40,000 (derivative) · Disposition to issuer (D): 20,500 (derivative) | EDGAR |
| 2023-06-09 | 4 | Omega Therapeutics, Inc. (OMGA) | Grant/award (A): 18,118 (derivative) @ $0 | EDGAR |
| 2023-06-02 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | Prometheus Biosciences, Inc. (RXDX) | Grant/award (A): 2,071 @ $0 | EDGAR |
| 2022-06-23 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Omega Therapeutics, Inc. (OMGA) | Grant/award (A): 18,118 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | Prometheus Biosciences, Inc. (RXDX) | Grant/award (A): 20,500 (derivative) @ $0 | EDGAR |
| 2021-06-23 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2021-03-11 | 4 | Prometheus Biosciences, Inc. (RXDX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-01-13 | 4 | Coherus BioSciences, Inc. (CHRS) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-04 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1410289 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs